Deschloroketamine

Deschloroketamine, usually shortened to DCK, is ketamine with the chlorine atom removed from the phenyl ring. It is a non-competitive NMDA receptor antagonist like its parent and produces a recognisably similar dissociative state, with two differences that matter more than the chemistry suggests: it is more potent by weight, and it lasts considerably longer.

It is a research chemical rather than a medicine. It has never been through clinical development, has no approved use anywhere, and is sold under the standard not-for-human-consumption framing. Its analytical characterisation came from forensic chemistry rather than pharmacology, when laboratories needed to identify what was appearing in seized samples ^[10], and the methods for detecting it in blood and hair were developed alongside those for its close relatives ^[11].

The duration is the practical hazard. A dissociative that outlasts ketamine by hours, taken by people whose expectations are calibrated to ketamine, is a compound people redose on before the first dose has finished arriving. Reports of compulsive use patterns and of urinary tract damage of the kind heavy ketamine use causes both follow from that, and neither has the clinical literature behind it that ketamine's harms do, because nobody has studied this compound in people.

As an NMDA antagonist it impairs coordination and judgment and can produce a dissociative 'hole' at higher doses, with risks of falls, vomiting while sedated, and loss of awareness; its longer duration means impairment lasts longer than ketamine. Repeated use of ketamine-type drugs is linked to bladder and urinary-tract damage and compulsive redosing. It is dangerous combined with other depressants such as alcohol, opioids, or benzodiazepines. Not medical advice.

Arylcyclohexylamines without the chlorine substituent were explored during the same mid-century programmes that produced phencyclidine and then ketamine, so the molecule itself is not new; what is new is its sale. Deschloroketamine appeared on the research chemical market in the mid-2010s, part of a wave of ketamine analogues that followed tightening controls on ketamine itself in several jurisdictions.

Its formal characterisation dates from that period and came from forensic laboratories rather than from drug discovery: a 2016 paper established its identity by gas chromatography, high-resolution mass spectrometry and nuclear magnetic resonance, which is the point at which analysts could reliably distinguish it in seized material ^[10]. Detection methods for blood and hair followed, developed together with those for 2-fluorodeschloroketamine and methoxpropamine as the analogue market diversified ^[11].

It has since been brought under control in a number of countries, generally through analogue provisions or scheduled additions rather than through any individual assessment of the compound. No clinical development has ever been attempted.

Within the community that uses dissociatives, DCK is known for one thing above all: it lasts. That is discussed as a feature by some users and is the source of most of the trouble reported with it, because a compound that comes on slowly and stays for many hours invites redosing during the onset, and redosing is the pattern that drives both compulsive use and urinary damage.

It also has a reputation for potency by weight, which matters more for an unregulated powder than it would for a measured medicine; the margin between an intended amount and several times that amount is narrower than with ketamine. There is essentially no medical or scientific reputation to report, because there is no clinical literature: the published record is analytical chemistry and forensic toxicology, not pharmacology in people ^[10][11]. Claims circulating about it being gentler on the bladder than ketamine have no published support, and the same claim was made for methoxetamine and did not hold.